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Abstract: Acute intermittent porphyria (AIP) is due to a deficiency of the third enzyme, the 
hydroxymethylbilane synthase, in heme biosynthesis. It manifests with occasional neuropsy-
chiatric crises associated with overproduction of porphyrin precursors, aminolevulinic acid 
and porphobilinogen. The clinical criteria of an acute attack include the paroxysmal nature and 
various combinations of symptoms, such as abdominal pain, autonomic dysfunction, hypona-
tremia, muscle weakness, or mental symptoms, in the absence of other obvious causes. Intensive 
abdominal pain without peritoneal signs, acute peripheral neuropathy, and encephalopathy usually 
with seizures or psychosis are the key symptoms indicating possible acute porphyria. More than 
fivefold elevation of urinary porphobilinogen excretion together with typical symptoms of an acute 
attack is sufficient to start a treatment. Currently, the prognosis of the patients with AIP is good, 
but physicians should be aware of a potentially fatal outcome of the disease. Mutation screening 
and identification of type of acute porphyria can be done at the quiescent phase of the disease. 
The management of patients with AIP include following strategies: A, during an acute attack: 
1) treatment with heme preparations, if an acute attack is severe or moderate; 2) symptomatic 
treatment of autonomic dysfunctions, polyneuropathy and encephalopathy; 3) exclusion of pre-
cipitating factors; and 4) adequate nutrition and fluid therapy. B, during remission: 1) exclusion 
of precipitating factors (education of patients and family doctors), 2) information about on-line 
drug lists, and 3) mutation screening for family members and education about precipitating 
factors in mutation-positive family members. C, management of patients with recurrent attacks: 
1) evaluation of the lifestyle, 2) evaluation of hormonal therapy in women, 3) prophylactic heme 
therapy, and 4) liver transplantation in patients with severe recurrent attacks. D, follow-up of the 
AIP patients for long-term complications: chronic hypertension, chronic kidney insufficiency, 
chronic pain syndrome, and hepatocellular carcinoma.
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Introduction
Acute intermittent porphyria (AIP) is a rare inherited metabolic disease due to a 
deficiency of the hydroxymethylbilane synthase (HMBS) in heme biosynthesis.1 AIP 
manifests after the puberty with occasional neuropsychiatric crises associated with 
accumulation of porphyrin precursors such as δ-aminolevulinic acid (ALA) and por-
phobilinogen (PBG) which are released from the liver into the circulation1,2 (Figure 1). 
The diagnosis is often delayed, because clinical manifestations are unspecific2 and 
commonly mimic acute encephalopathy or abdominal crisis of other origin.3
AIP is the most common type of acute porphyrias in most of the countries 
 worldwide.1 The major clinical manifestation of AIP is an acute attack, which is 
clinically indistinguishable from those caused by other acute porphyrias: variegate 
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porphyria (VP) and hereditary coproporphyria (HCP).2 The 
management of an acute attack in each disease is similar,2 
and thus, more specific classification of an acute porphyria 
can be done in remission. Photosensitivity and skin fragility 
found in patients with cutaneous porphyrias, VP and HCP, 
occur independently of acute attacks and do not occur in 
AIP.4,5
When acute porphyria is suspected, biochemical plasma 
or urinalyses of porphyrin precursors are mandatory to con-
firm the diagnosis of an acute porphyric attack.2 More than 
five-fold elevation of urinary PBG excretion together with 
typical symptoms of an acute attack is sufficient to start a 
treatment,6 but in each case other causes of abdominal crisis 
must be excluded before a specific treatment of an acute 
attack is administered. Plasma porphyrin spectrum is a 
valuable tool to confirm the diagnosis in the early phase and 
helps to identify different subtypes of acute porphyrias dur-
ing an acute attack.7 In AIP emission peak is only transient, 
and if taken late, may be negative leading to misdiagnosis. 
AIP and HCP cannot be distinguished by plasma analysis. 
Mutation screening can be done at the quiescent phase of 
the disease (Table 1).
Currently, the prognosis of patients with AIP is good even 
in severe attacks,3,8–12 but physicians should be aware of a 
potentially fatal outcome of the disease.10 During remission 
the majority of the patients experience no clinical symptoms. 
Hypertension, chronic kidney insufficiency, chronic pain 
syndromes, and hepatocellular carcinoma (HCC) may be 
long-term complications of AIP.3,8,13–15
The management of patients with AIP include following 
strategies:
A. During an acute attack: 1) treatment with heme 
preparations, if an acute attack is severe or moderate; 
2) symptomatic treatment of autonomic dysfunctions, 
sensorimotor neuropathy and encephalopathy; 3) exclu-
sion of precipitating factors; and 4) adequate nutrition 
and fluid therapy.
B. During remission: 1) exclusion of precipitating factors 
(education of patients and family doctors), 2) informa-
tion about on-line drug lists, and 3) mutation screening 
for family members and education about precipitating 
factors in mutation-positive family members which 
can diminish mortality and prevent subsequent attacks 
among them.
Pathogenesis of an acute attack Key
enzymes
Glycine + succinyl-CoA
↑↑↑ δ-aminolevulinic acid
(ALA)
↑↑↑ δ-aminolevulinic 
acid synthase 
(ALAS) during
an acute
porphyric 
attack
↑↑↑ ALAS transcription in the liver
Unknown mechanism
Feedback regulation via ↓ ALAS activity
↑↑↑ Heme consumption
↑↑↑ Porphobilinogen
(PBG)
[Hydroxymethylbilane]
Fasting/low caloric dietDrugs
alcohol
Direct
Direct
Indirect via peroxisome-proliferator-
activated receptor γ coactivator 1α (PGC-1α)
Indirect via activation of liver heme
oxygenase (↑ heme decay)
Drugs metabolizing
via CYP 450
Infections
stress
Hormonal fluctuation during menstrual cycle and pregnancy
↓Hydroxymethylbilane
synthase
(HMBS)
Permanently in 
patients with AIP Uroporphyrinogen III
Coproporphyrinogen III
Protoporphyrinogen IX
Protoporphyrin IX
Heme
Heme biosynthesis
pathway
Figure 1 Precipitating factors and pathogenesis of an acute attack in AiP.
Notes: Several exogenic and endogenic factors induce heme biosynthesis via direct or indirect activation of ALA synthase. In AIP patients with inherited deficiency of HMBS, 
this results in accumulation of neurotoxic porphyrin precursors (ALA and PBG) in tissues and circulation. Heme, the end product of heme biosynthetic pathway, regulates 
transcription of ALA synthase via negative feedback and can be used in the treatment of an acute attack.
Abbreviation: AiP, acute intermittent porphyria.
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C. Management of patients with recurrent attacks: 1) evalu-
ation of the lifestyle, 2) evaluation of hormonal therapy 
in women, 3) prophylactic heme therapy, and 4) liver 
transplantation in AIP patients with severe recurrent 
attacks.
D. Follow-up of the AIP patients for long-term complica-
tions: chronic hypertension, chronic kidney insufficiency, 
chronic pain syndrome, and HCC.
Clinical manifestations and 
pathogenesis of an acute attack
The majority of acute attacks manifest as a combination 
of abdominal pain, mild mental symptoms, and autonomic 
dysfunction.2,6 Both acute peripheral neuropathy and severe 
encephalopathy may develop, if an acute attack proceeds10,11,16 
(Figure 2). It is usually iatrogenic, mainly due to administra-
tion of porphyrinogenic drugs when the diagnosis of acute 
porphyria is delayed.10,11,16 Both endogenous and exogenous 
factors, such as certain medications, alcohol, infections, low 
caloric intake, or changes in sex hormone balance during the 
menstrual cycle or pregnancy, can provoke clinical manifes-
tations in AIP8,17 (Figures 1 and 2). All these factors induce 
heme synthesis either directly or indirectly via activation of 
ALA synthase in the liver18 resulting in accumulation of por-
phyrins and their precursors in the tissues and circulation.
Excess of ALA is the most potential candidate to cause 
neuronal damage and could be responsible for autonomic 
and peripheral neuropathy and encephalopathy via multiple 
mechanisms.19 Results from both the experimental and 
clinical data support the direct neurotoxicity of ALA, but 
also modification of γ-aminobutyric acid (GABA)-ergic 
system due to the structural similarity of ALA and GABA/
glutamate,20 as well as formation of free radicals and reactive 
oxygen species from ALA21 may play a role in the pathogen-
esis of an acute attack.
Нeme preparations, in the current treatment, lead to a 
rapid decrease of synthesis of porphyrin precursors via nega-
tive feedback (Figure 1).6 Reduced transcription of ALA syn-
thase in the liver achieved by heme results in cessation of an 
acute attack within few days.6 Dose-dependent administration 
of glucose has also been shown to downregulate ALA syn-
thase in experimental conditions via peroxisome-proliferator-
activated receptor γ coactivator 1α (PGC-1α), a protein 
which directly induces transcription of ALA synthase 1.22 
Table 1 The laboratory investigations to confirm AIP and other acute porphyrias
  I.  Screening tests during an acute attack
   U-PBG (always elevated, at least . fivefold, usually .50-fold compared to reference values)
   P-porphyrin emission spectrum (peak at 615–620 nm in AiP and HCP, 624–627 nm in VP)
Positive results 
Together with typical severe to moderate clinical manifestations of an acute attack is sufficient to start the treatment of acute porphyria with heme 
preparations
 II.  Additional tests (elevated in an acute attack)
   U-ALA During an acute attack Always elevated but less than U-PBG
   U-porphyrins in AiP: U-uroporphyrin (I and III) . U-coproporphyrin (I and III)
in HCP: U-coproporphyrin (I and III)
in vP: U-coproporphyrin (I and III) . U-uroporphyrin (I and III)
   F-porphyrins in AiP: F-protoporphyrin (increased in 20% of the patients with AIP)
in vP: F-protoporphyrin . F-coproporphyrin
in HCP: F-coproporphyrin (iii:i.2)
   B-porphyrin no need to test in acute porphyria
III.   Specific tests in remission
   enzymes: in AiP: Erc-HMBS (,50% in ∼84%–95% of AIP patients, can be normal)
in vP: Ly-PPOX
in HCP: erc-CoproOX
   DNA analysis for specific mutations:
in AiP: HMBS gene
in vP: PPOX gene
in HCP: CoproOX gene
Abbreviations: AIP, acute intermittent porphyria; U-PBG, porphobilinogen in urine; U-ALA, δ-aminolevulinic acid in urine; B-, whole-blood metabolites; P-, metabolites in 
plasma; U-, metabolites in urine; F-, metabolites in feces; HCP, hereditary coproporphyria; VP, variegate porphyria; HMBS, hydroxymethylbilane synthase; Erc-HMBS, HMBS 
activity in erythrocytes; PPOX, protoporphyrinogen oxidase; Ly-PPOX, PPOX activity in lymphocytes; CoproOX, coproporphyrinogen oxidase; erc-CoproOX, CoproOX 
activity in erythrocytes.
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Subsequently, glucose infusions have been used to prevent 
fasting and may be sufficient in mild attacks. Despite the 
fact that recombinant human-HMBS-enzyme (rh-HMBS) 
therapy decreased the plasma level of PBG rapidly, it had no 
effect on the ALA level23 or the patients’ acute symptoms. In 
contrast, liver transplantation immediately corrects porphyrin 
metabolism to normal demonstrating the dominant role of 
liver as a source of ALA.24
The exact mechanism of cyclic attacks in women is 
unknown. Despite the level of sex hormones is at the highest 
during the second and third trimester, acute attacks are rare 
during pregnancy.3,8,17,25 Although, especially, progesterone is 
known to be a potent inducer of ALA synthase,26 the direct 
role of sex hormones as sole precipitating factors is unlikely.27 
Moreover, cyclical attacks occur mainly in premenstruum 
when the levels of estrogen and progesterone fluctuate the 
most, and usually are resolved during early menstruation.8,17 
Individual variation in the progesterone metabolism may play 
a role in clinical manifestations of AIP.28 Cytochrome-P450 
activities in the liver also vary individually and can result in an 
abnormal level or ratio of sex hormones affecting the feedback 
mechanism to hypothalamus. Several neurotransmitters control 
the menstrual cycle through the regulation of pulsatile release 
of gonadotropin-releasing hormone (GnRH) and other clock 
mechanisms in the hypothalamus.29 This interaction may acti-
vate abnormal liver metabolism,30 and consequently precipitate 
acute attacks by the central mechanism making AIP a central 
nervous system disorder in addition to a liver disease.27
Diagnosis of AIP
The clinical criteria of an acute attack include the paroxys-
mal nature of the symptoms with abdominal or back pain 
associated with one or more signs of autonomic dysfunc-
tion, hyponatremia, muscle weakness, or mental symptoms6 
(Table 2).
The biochemical criteria of an acute attack include more 
than a fivefold increase of urinary PBG excretion (Table 1), 
Clinical
severity
of the 
symptoms
Duration of
an acute attack
Drugs Drugs
Heme preparationsDrugs
Menstrual cycle
Alcohol
Infections
Abdominal
pain
Autonomic
dysfucnction
Mental
symptoms
Progression
Progression
Plateau
Plateau
<30 d
<30 d
3–21 d
Motor polyneuropathy, seizures, focal CNS involvement
Figure 2 Staging of an acute attack in connection with precipitating factors and recommendations of heme therapy.
Note: Treatment with heme preparations: recommended (thin solid arrow), usually unnecessary (dotted arrow), influence of precipitating factors and connection with 
staging of acute attack (thick gray arrow).
Abbreviations: CNS, central nervous system; d, days.
Table 2 The key symptoms indicating acute porphyria
intensive acute or recurrent abdominal pain without peritoneal signs or 
other obvious causes, especially if associated with
•  Dysautonomia (tachycardia, hypertension, nausea, vomiting, 
constipation)
•  Dark urine (due to porphyrins)
•  Any neurological or psychiatric manifestation
•  Hyponatremia
Hypertensive crisis
•  Associated with abdominal pain
Acute or recurrent motor/sensorimotor polyneuropathies, especially if 
associated with
•  Abdominal pain or dysautonomia, commonly preceding neuropathy
•  Signs of central nervous system involvement
•  Hepatopathy or hyponatremia
•  Mainly axonopathy on nerve conduction studies
•  Normal cerebrospinal fluid
Acute encephalopathy with no obvious etiology, especially if associated with
•  Dysautonomia or pain
•  Posterior reversible encephalopathy syndrome (PRES) on brain 
magnetic resonance imaging (MRI) or normal MRI
•  Normal cerebrospinal fluid
epileptic seizures or acute psychosis as a sign of acute encephalopathy 
with no obvious etiology, especially if associated with
•  Hyponatremia
•  Drug resistant
•  Premenstrual
Rhabdomyolysis with no obvious etiology, especially if associated with
•  Abdominal pain
•  Hyponatremia
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which can be detected by a simple Watson-Schwartz or 
 Hoesch qualitative test.31 The results should be confirmed 
by a quantitative measurement of urinary PBG, since 
false positive results in these screening tests are possible, 
especially, if perchloric acid instead of amyl alcohol is used 
as an extract.31–33 If the urine samples are not sheltered from 
the light, urinalysis may become false negative.31–33
Urinary excretion of PBG is elevated in 88% of the 
patients with AIP in remission.34 During an acute attack 
PBG excretion increases commonly at least two- to fourfold 
from the values found in remission.34 Urinary ALA is always 
increased during an acute attack but remains elevated only in 
61% of AIP cases in remission.34 In AIP, urinary excretion of 
uroporphyrins is increased, including both I and III isomers, 
and exceeds that of coproporphyrins I and III.34
Of note, abnormal metabolism of porphyrin and their 
precursors may also be detected in patients with hepatopathy 
or heavy metal intoxications.31,35 The clinical manifestations 
may even resemble AIP,36 but biochemically only a mild 
to moderate coproporphyrinuria is present, and porphyrin 
precursors are commonly only transiently elevated.35,36 If 
urinary ALA level exceeds that of PBG significantly, lead 
intoxication should be excluded.31
In AIP, plasma porphyrin emission spectrum test 
with excitation wave length of 405 nm shows a peak at 
615–620 nm during an acute attack similar to HCP but it 
can be less frequently found in remission.32,34 Emission peak 
is due to porphyrins’ ability to absorb light at wave length 
around 400 nm and their emission as red fluorescence, at 
around 600 nm.37 Plasma emission spectrum test is used 
mainly to exclude symptomatic VP, since it has a unique 
624–627 nm spectrum due to protein-associated plasma por-
phyrins.31,32,38 Of note, emission peak is commonly negative 
at the asymptomatic phase of VP.
Around 20% of the patients with AIP have moderately 
increased excretion of fecal protoporphyrin, which is less 
prominent than that of VP patients.5,34 Since fecal copropor-
phyrin level is usually normal in AIP,34 more than tenfold 
excretion of coproporphyrin (isoform III:I .2) in feces 
together with protoporphyrin suggests HCP.4
In 84%–95% of patients with AIP,34,39 erythrocyte 
HMBS (Erc-HMBS) activity has been lower than normal. 
In the variant form of AIP (5%–16% of all patients),34,39 
Erc-HMBS activity was normal due to an alternative splic-
ing of the HMBS gene in erythroid cells.40 HMBS activity 
should be assayed in remission, since erythropoiesis may 
be enhanced during an attack as well as in hypochromic 
or hemolytic anemias and hepatopathy.33,41 In contrast, 
it can be decreased in non-porphyric individuals with 
sideropenia.33
DNA analysis is the most reliable method to confirm AIP 
in the patients and their symptom-free relatives.34,42 The direct 
sequencing of the HMBS gene is used to identify a mutation 
in the proband and the asymptomatic gene carriers among the 
family members.42 The sensitivity of the mutation analysis is 
90%–100%.34,43,44 To date, 391 mutations have been reported 
in the HMBS gene,45 and therefore DNA testing in an index 
case of a family is perhaps more laborious and time consum-
ing, but afterward mutation analysis may easily reveal several 
family members at risk.
Treatment of an acute attack
Current treatment options include heme preparations dur-
ing an acute attack, which may be life-saving, especially if 
encephalopathy or polyneuropathy develop.2 The treatment 
should be started immediately during a severe or moderate 
acute attack after the demonstration of typical symptoms of 
acute porphyria and more than fivefold elevation of urine 
PBG shown by qualitative tests.6 Other causes of abdomi-
nal crises and neuropsychiatric symptoms often demanding 
other specific and rapid interventions should always be 
excluded.
Only around 30%–50% of the patients with a mutation 
in the HMBS gene have mild or moderate clinical symptoms 
of AIP during their life span.8,17,46 Less commonly, around 
3%–5% of the patients with AIP17,47 have recurrent severe 
attacks, and no time for neuronal recovery. These patients 
are at a high risk for chronic pain syndrome. The onset and 
clinical outcome of an attack is commonly influenced by 
several exogenous factors simultaneously, and endogenous 
factors, such as the residual activity of a mutated protein, 
individual differences in other metabolic pathways in the 
liver and in neuronal protection capacity, may modify the 
clinical outcome.12,34
Heme
Heme preparations have been used for acute attacks for 
more than three decades without tolerance.3,6,48,49 Hemin 
is isolated and purified from human red cell concentrates. 
In Europe, Asia, and South Africa, hemin is commercially 
available as heme arginate (Normosang®, Orphan Europe 
SARL, Puteaux, France) and in Northern America as lyo-
philized hematin (Panhematin®, Ovation Pharmaceuticals 
Inc., Deerfield, IL, USA).
In an open series of 22 patients, the patients treated with 
heme arginate6 recovered more rapidly in comparison with 
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those treated with glucose infusions in the earlier series.50–53 
Safety and efficiency of lyophilized hematin has also been 
demonstrated in six open-labeled studies involving over 200 
AIP patients.48 The only study using a placebo-controlled 
series found insignificant benefit of heme arginate for the 
analgesic requirement, pain score, and duration of the hospital 
stay.54 The validity of the trial has been questioned6 due to 
small number of patients (eleven patients treated with heme 
and ten with a placebo), a high proportion of the patients 
with peripheral neuropathy in this series (43%), delayed 
administration of preparation (.2 days after admission), 
and difficulties in arranging a placebo, which resembles 
heme arginate.
Heme arginate and lyophilized hematin are usually 
infused daily (3–4 mg/kg) into a large peripheral vein or 
venous access port for 3–4 consequent days, but a repetitive 
course may be required if porphyric symptoms are still pro-
gressing6,48 (Table 3). Concentrated solution of heme arginate 
is mixed with 100 mL physiological saline, and lyophilized 
hematin is reconstituted with sterile water before infu-
sion.6,48,55 Lyophilized hematin should be used immediately 
after reconstitution. Heme arginate should also be used soon 
after dilution, since it becomes unstable and may aggregate. 
In both cases, addition of human serum albumin may be 
beneficial in order to diminish the risk of phlebitis at the site 
of infusion. After infusion, the vein should be washed with 
saline for 10–15 minutes. For the long-term use of heme, 
a central access catheter (tunneled catheter or portacat) may 
be useful. Low molecular weight heparin can be used sub-
cutaneously to prevent or treat thrombophlebitis.
The treatment with heme preparations should be started 
without delay, but even in the late stage of progressing motor 
neuropathy, it is efficient.10 If a patient’s neurological condi-
tion has stabilized (plateau phase, Figure 2), an additional 
treatment with heme is rarely necessary but other causes such 
as infections may deteriorate the patient’s clinical condition 
and should be treated properly.
The reported side effects include mild coagulopathy,56 
thrombophlebitis,6 and anaphylactic shock in one case.57
High carbohydrate loading and 
supportive treatment
The treatment of acute attacks with high carbohydrate diet 
or infusions (300–500 g/day) has been in use in order to 
downregulate the activity of ALA synthase and prevent 
 fasting.58 High dose of glucose should be infused continu-
ously 24 hours per day with an automatic syringe, and blood 
sugar level should be monitored regularly to avoid hyper- or 
hypoglycemia causing additional neurological  complications. 
If a patient is able to eat, carbohydrate rich meals may simi-
larly have a beneficial effect.
Currently, the use of glucose is limited only to mild 
attacks (ie, mild pain, no paresis, seizures, or hyponatremia) 
according to the guidelines for the treatment of an acute attack 
in the USA and South Africa, or if heme arginate or hematin 
are not available locally11,59 (Table 3). In mild cases, the dose 
of glucose can be lower than discussed earlier. If glucose infu-
sions do not result in clinical remission within a day or two, 
Table 3 Clinical manifestations and treatment of an acute attack
Signs and symptoms Medications
 I.  Specific therapy Heme preparations (3–4 mg/kg/d for 3–4 
consequent days) if opiates are insufficient, 
or an acute attack is proceeding
 ii.  High carbohydrate 
loading and supportive 
treatment
Glucose and other fluid infusions and 
follow-up of electrolytes, carbohydrate 
rich food
iii.  Symptomatic therapy
Autonomic neuropathy
Abdominal and/or  
back pain
Opiates iv/im bolus or in severe cases as 
infusion
Tachycardia, arrhythmia Beta blockers, telemetry
Hypertension Beta blockers, clonidine
Constipation Lactulose
vomiting Phenothiazine,a olanzapine, lorazepam
Urinary retention Urethral catheter
Peripheral neuropathy
Respiratory muscle paresis Mechanical ventilation
Pneumonia Antibioticsa except sulfonamides
Muscle weakness Rehabilitation
Cranial neuropathy Nasogastric tube for the bulbar paresis
Pain in extremities,  
back pain
Opiates, paracetamol, anti-inflammatory 
drugs
Numbness in extremities
Encephalopathy
Mental changes
insomnia and/or anxiety Most benzodiazepinesa including zopiclone
Hallucinations Phenothiazines,a olanzapine
Convulsions Correction of hyponatremia and 
hypertension, diazepam
Gabapentin, levetiracetam if prolonged 
treatment is needed
Metabolic changes
Hyponatremia (SIADH) P-Na .125 mmol/L: water restriction due 
to syndrome of inappropriate antidiuretic 
hormone secretion (SIADH)
P-Na #125 mmol/L or patients with 
seizures or unconscious: infusion of saline. 
Correction #12 mmol/L/day. Be aware of 
pontine myelinolysis
Acute renal failure Fluid therapy, hemodialysis
Rhabdomyolysis Fluid therapy
Hepatopathy Follow-up of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST)
Dark urine Follow-up of U-PBG and U-ALA
Note: aMost of the medications in the group are well tolerated.
Abbreviations: iv/im, intravenous/intramuscular; U-PBG, porphobilinogen in urine; 
U-ALA, δ-aminolevulinic acid in urine.
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or if an acute attack is severe at the onset, heme preparations 
should be used. Mild or clearly resolving attacks with minor 
pain or anxiety may be treated symptomatically.60
Low to moderate dose of glucose and saline infusions 
should be used as supportive treatment to prevent  dehydration 
and during fasting if the patient is unable to drink.49 
The amount of daily fluids may vary from restricted fluid 
intake in a case of inappropriate antidiuretic hormone secre-
tion to rapid restoration of intravascular volume and correc-
tion of electrolyte disturbances in rhabdomyolysis-induced 
renal failure.61 Thus, fluid restoration must be tailored 
individually and careful monitoring of water and electrolyte 
balance, including sodium, potassium, and magnesium, 
and renal function should be done (Table 4). Mild to severe 
hyponatremia is a rather common phenomenon (25%–60%) 
during an acute attack,10,11,50–53 and should be corrected slowly 
(,12 mmol/L/24 h)61,62 because of potential pontine myelinol-
ysis, a condition also described in a patient with AIP.62
Rhabdomyolysis during an acute attack is often 
neglected,61 but can be easily diagnosed by measurement 
of plasma myoglobin or creatinine kinase level and should 
be treated according to the guidelines. Acute kidney insuf-
ficiency is a rare but a severe complication of an acute attack, 
and may proceed to hemodialysis.11,15,63
Elimination of precipitating factors
All potentially precipitating factors such as drugs, smok-
ing, and alcohol should be eliminated during an acute 
attack. Infections should be treated promptly and caloric 
intake of a patient should be sufficient to avoid fasting.2,49,59 
Administration of porphyrinogenic drugs commonly results 
in proceeding of an acute attack to neuropathy or encephal-
opathy (Figure 2). Several lists of potentially safe and unsafe 
drugs are available on the Internet.64–67
Some drugs, such as barbiturates and sulfonamides, 
are strictly forbidden since their use has been associated 
with several severe attacks. Most of the drugs, however, 
are classified as potentially porphyrinogenic, since clinical 
data about their safety in acute porphyria is lacking. The 
majority of the patients, especially asymptomatic, toler-
ate many drugs well; thus, total avoidance of drugs for the 
safety reasons leads to inappropriate treatment of patients’ 
other diseases. Antibiotics excluding sulfonamides, drugs 
for cardiovascular diseases, and pain killers are usually well 
tolerated in addition to preparations used in oncology. The 
follow-up of urinary excretion of porphyrin precursors may 
elucidate the effect of a drug on the heme biosynthesis but 
increased excretion of porphyrin metabolites without clini-
cal symptoms should not solely determine its use. In each 
case the potential risk and advantage of a drug should be 
evaluated by a clinician.
Symptomatic therapy
Symptomatic therapy for pain, hypertension, tachycardia, 
nausea, and vomiting is commonly required (Table 3).2,49 
Abdominal pain is usually intensive (visual analog scale, 
VAS .7 cm, scale from 0 to 10 cm)68 and opiates are needed. 
Morphine, pethidine, oxycodone, tramadol, and fentanyl 
have been used without complication. Paracetamol and anti-
inflammatory drugs can be used in mild cases.
Beta blockers are commonly used for tachycardia and to 
prevent arrhythmia. If a hypertensive crisis develops, it can 
be treated with beta blockers or clonidine or other drugs rec-
ommended by the current guidelines.69 Nausea and vomiting 
can be controlled by olanzapine, lorazepam, or prochlorpera-
zine.2,49 Domperidone has been used during an acute attack, 
but interactions with opiates and other drugs increasing the 
risk for arrhythmias may prevent its use. Metoclopramide 
has been associated with neuropathy and encephalopathy 
during a few acute attacks,70 but some patients have used it 
without complications.66 Urinary retention is quite common 
and can be treated with catheterization. Blood pressure, heart 
rate, pain score by visual analog scale,68 and severity of the 
muscle weakness should be evaluated daily at the bed side. 
Bulbar paresis, proceeding muscle weakness, and arrhythmia 
are signs of progression of an acute attack and the patient 
should be transferred to the intensive care unit.10 Respiratory 
insufficiency as a sign of motor neuropathy increases risk of 
Table 4 Signs, symptoms, and metabolites followed during an 
acute attack
To be followed Severe complication
Signs and symptoms
Pain, vAS  
Blood pressure
Heart rate, telemetry
Hypertensive crisis
Palpitation, arrhythmia (atrial or ventricular)
Defecation Constipation, paralytic ileus
Urination Urinary retention, bladder paresis, oliguria
Respiratory rate
Oximetry
Neurological status
electrolyte imbalance
Respiratory insufficiency, pneumonia 
Hypoxemia
Tetraparesis, bulbar palsy, seizures, 
unconsciousness, hallucinations
Hyponatremia, SiADH, renal failure
Metabolites
K, Na, Mg, Ca  
Glucose
Hyponatremia, hypokalemia/hyperkalemia, 
hypomagnesemia
Hypoglycemia/hyperglycemia
Creatinine  
CK
Acute renal failure, interstitial nephritis 
Rhabdomyolysis
ALT Mild hepatopathy
Abbreviations: vAS, visual analog scale, from 0 to 10 cm; CK, creatinine kinase; 
ALT, alanine aminotransferase; SiADH, syndrome of inappropriate antidiuretic 
hormone secretion.
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pneumonia and may require early mechanical ventilation. 
Patients with paresis due to neuropathy or encephalopathy 
require rehabilitation therapy even in the early phase.
Epileptic seizures, which are usually generalized, can 
be treated with intravenous diazepam, gabapentin, leve-
tiracetam, or propofol if status epilepticus develops.2,49,59 
Usually there is a single or few transient seizures, which 
associate with acute encephalopathy visualized as posterior 
reversible syndrome in brain magnetic resonance imaging 
(MRI) and does not require anticonvulsive treatment in the 
follow-up.16 Correction of hyponatremia may be beneficial 
in patients with seizures (Tables 3 and 4). Insomnia and 
anxiety are usually mild and do not require additional 
medications but can be treated with benzodiazepines, 
such as lorazepam.49 Hallucinations are also signs of acute 
encephalopathy and should be treated with phenothiazine 
or olanzapine.
Prognosis of an acute attack
Duration of the diagnostic delay of an acute attack correlates 
with a fatal outcome10 mainly due to the administration of 
drugs known to precipitate AIP for a misdiagnosed attack. 
The causes of death are related to complications of prolonged 
ventilation and cardiac arrest.10,11,50,51,53 The majority of 
patients display full functional recovery even after a severe 
attack.10
The mortality has decreased dramatically during the last 
decades among diagnosed AIP patients by 5%–20% during 
an acute attack,3,8–11 but it is still a potentially fatal disease.
Prevention of acute attacks
Avoidance of precipitating factors
In remission, patients may tolerate medications classified as 
potentially unsafe and alcohol, but if porphyric symptoms 
appear their use should be restricted.8,17,49 The education of 
patients and their family doctors about precipitating factors, 
including the information of safe and unsafe drugs, neces-
sity of prompt treatment of infections, healthy lifestyle with 
regular normocaloric diet, avoidance of alcohol, if porphyric 
symptoms occur, and smoking, reduction of excessive stress 
are essential for patients’ prognosis.8,17,49 In the treatment of 
obesity, the patients with AIP should include carbohydrates 
into their diet, and the weight reduction should be done 
slowly.
DNA diagnostics among family members is recom-
mended before the adulthood, since it decreases the likeli-
hood of an acute attack to 5% in patients diagnosed at the 
presymptomatic phase.12 The prenatal screening in families 
with AIP is not recommended because of a low risk of severe 
attacks among mutation carriers12 and good therapy options 
even if acute attacks would develop.49
Prevention of cyclical recurrent 
attacks
In women with AIP, the menstrual cycle is the most common 
precipitating factor (10%–39%) manifesting usually with 
1–3 months interval in premenstruum.8,17 In the majority 
cases, these attacks are mild and do not require hospitalization. 
Irregular cycles due to hormonal imbalance may predispose 
to cyclical attacks. However, in 3%–5% of the women cyclical 
attacks are severe and frequent (up to 2–4 weeks interval),17,47 
which disable their lives. If the patient has recurrent attacks 
preventive therapy is needed.
evaluation of the lifestyle
Usually these women have several precipitating factors simul-
taneously. It is important to first correct lifestyle, indicating 
cessation of smoking and use of alcohol or any medication 
or homeopathic drug which may be porphyrinogenic. Since 
body mass index (BMI) is commonly at the low or low normal 
level among women with recurrent attacks, gaining weight, 
at least a few kilos, may be beneficial to balance energy 
metabolism. Patients should avoid fasting and potential 
hypoglycemia by regular eating habits.
evaluation of hormonal therapy in 
women
The exogenous hormonal therapy can be used, if lifestyle 
changes are insufficient to prevent attacks. Contraceptive 
pills have been used for prophylaxis of recurrent acute attacks 
for many years,8,71 but not all women respond to this therapy 
even after 3 months of use. We have used ethinyl estradiol-
levonorgestrel preparation successfully, and the responders 
have tolerated them well, even for years. About 46%–58% of 
the Finnish and Swedish women with AIP and VP have used 
hormonal pills for contraception,8,17 and the majority of them 
have had no complications in remission despite use of vari-
ous progesterone compounds in combination with estrogen 
preparations. Intrauterine devices including levonorgestrel 
have not been reported to cause porphyric symptoms.17 
Based on our results, we have let our patients use hormonal 
contraception under supervision.
Of note, contraceptive pills can also provoke acute attacks 
in 5%–14% of the women with both latent and manifest 
AIP (24% of selected women with previously manifest 
AIP),8,17 and as such many guidelines recommend not to use 
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them.49,66,67 Tolerance to progesterone preparations may vary 
individually but estrogen preparations, especially used for 
menopausal symptoms, do not usually precipitate porphyric 
symptoms.17,71 Thus, it is important that the risk for potential 
complications and benefits of hormonal therapy are evaluated 
individually by a clinician. Excretion of porphyrin precursors 
should be controlled and hormonal preparations should be 
stopped, if symptoms suggestive for acute porphyria occur 
during their use.
In contrast, GnRH analogs inducing ovarian suppression 
are not porphyrinogenic and have been reported to dimin-
ish the severity and frequency of attacks in 60%–80% of 
the women.72–75 The responders have more frequently had 
regular menstrual cycles and pronounce decrease in the 
estradiol level after the treatment with GnRH analogs when 
compared to the women who have been nonresponders or 
have responded only to a high dose of the preparation.72,73 
Drug-induced menopause decreased the excretion of por-
phyrin precursors to 60% of the previous values in both 
groups.
The treatment should first be continued up to a few 
months, and thereafter its efficiency should be evaluated. If 
a longer period for treatment is needed, GnRH agonist can be 
combined with estrogen preparations to avoid osteopenia and 
other menopausal symptoms. Estrogen patches are preferred 
to avoid the first passage metabolism in the liver.  Progesterone 
should be administered regularly to avoid increased risk of 
endometrial cancer during the postmenopausal estrogen 
therapy, but they may also induce acute attacks during the 
combination treatment.74 Intrauterine device with levonorg-
estrel has been used without complications in this compound 
hormonal therapy,74 and another option is to lower the dose 
of GnRH analogs to sustain natural sex-hormone level, 
which could prevent the long-term side effects of the GnRH 
agonist.17,74 The patients should be followed carefully and 
efficiently, and side effects and need for the combination 
therapy should be evaluated at regular intervals. Women 
with cyclical attacks may also become asymptomatic after 
their natural menopause.17 Screening of urinary excretions 
of PBG and ALA may elucidate the biochemical activity of 
the disease, and maybe useful to follow.
Prophylactic heme therapy
Regular heme infusions commonly alleviate the severity and 
frequency of recurrent attacks.2,3,49 The aim of this treatment 
is to decrease substantially the level of porphyrin precursors 
in plasma. The majority of patients respond well but the 
long-term treatment may induce dependence on the exogenic 
heme. As a result, a patient may have increased need for heme 
from monthly to twice a week infusions and withdrawal of 
the treatment is difficult due to severe porphyric symptoms. 
Frequent administrations of heme preparations may lead to 
thrombotic complications of superficial veins, and assessment 
of a permanent central venous catheter may be necessary. 
Moreover, long-term treatment of heme may lead to iron over-
load and organ damage due to hemosiderosis. Progressing 
hepatopathy, heart failure, and endocrinopathies may develop. 
Follow-up of plasma ferritin and transferrin saturation levels 
is necessary, and computed tomography (CT) or MRI reveal 
iron load in organs. Venesections are usually poorly tolerated 
but iron chelates may be used.
Liver transplantation in AiP patients with 
severe recurrent attacks
If the standard treatment is unsuccessful or quality of life 
is unbearable, liver transplantation is an option for severely 
affected patients.24,49 Currently, more than ten AIP patients 
have undergone liver (or liver-kidney) transplantation since 
2004.24,49,76 It has been successful in the majority of cases 
resulting in immediate correction of abnormal porphyrin 
metabolism and cessation of attacks and chronic pain 
syndrome.24 Immunosuppressive drugs have been tolerated 
well by the patients, and their quality of life has improved 
dramatically. A few patients have died soon after liver 
transplantation mainly due to infections. Timing is also 
important in the liver transplantation. Patients should not 
wait too long in a too poor condition since the recovery 
from the operation and immunosuppression may associ-
ate with early complications such as infections or throm-
boembolic complications.76 If chronic motor neuropathy 
and encephalopathy have been present for years, the full 
recovery of neuronal damage may not be reached even 
after total normalization of porphyrin metabolism. Of note, 
partial liver transplantation has not corrected biochemi-
cal abnormalities or clinical manifestations permanently 
and should not be done.77 Moreover, transplantation of 
the HMBS deficient liver induced an abnormal porphyrin 
metabolism in a recipient.77
Management of pregnancies
Previously, pregnancies were commonly complicated by 
acute attacks mainly during the first trimester and postpar-
tum, and women with AIP were advised to avoid pregnancy. 
Currently, overall prognosis for pregnancy in AIP is good, 
especially if the diagnosis is known in advance and no por-
phyrinogenic drugs are used.8,17,25
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Cyclical attacks do not predict attacks during preg-
nancy, and pregnancy nowadays seldom precipitates acute 
attacks.8,17,25 Heme preparations have been used during 
pregnancy without fetal or maternal complications.11,27,49,78 In 
some women, who have experienced cyclical attacks for many 
years, recurrent attacks have stopped after the first trimester 
of pregnancy, and these women have been asymptomatic 
thereafter.17,27 Thus, pregnancy may act as a hormonal therapy 
and could be even considered as an option for the women 
with cyclical attacks.
Long-term complications of AIP
Hypertension and renal insufficiency
The prevalence of hypertension is significantly higher in 
patients with manifest AIP than in general population.3,8,79,80 
Thus, early monitoring of blood pressure and efficient treat-
ment with antihypertensive drugs is mandatory to avoid organ 
complications. This is especially crucial if renal failure is 
already present.
Monitoring of creatinine level in the follow-up of patients 
with manifested AIP shows mild to moderate elevation in 
10%–50% of the cases.8,79,80 This is significantly more com-
mon than in general population.3,8,9,15,63 Tubulointerstitial 
kidney disease has been the main presentation in a biopsy 
of the investigated cases.8,15,63 It has been commonly associ-
ated with recurrent acute attacks, hypertension, and use of 
anti-inflammatory drugs.8,15,63,80 The main recommendation 
for renal protection include adequate drinking regimen, blood 
pressure control, and avoidance of anti-inflammatory or 
other nephrotoxic drugs according to the general  guidelines. 
Patients with AIP and nephropathy, even mild, have an 
increased risk of deterioration of renal functions during an 
attack, and should be treated carefully with fluid therapy and 
hemodialysis if necessary.
Chronic hemodialysis may induce cutaneous symptoms 
in patients with AIP mimicking porphyria cutanea tarda 
(PCT).81 Since mainly ALA and PBG but not porphyrins 
have been filtered during dialysis, recurrent attacks were 
transformed to cutaneous manifestations in one patient.81 
Use of high-flux hemodialysis and erythropoietin substitu-
tion might be of help since they remove plasma porphyrins 
and have alleviated clinical manifestation in PCT patients 
with end-stage renal failure.82,83 Kidney transplantation84 or 
combined liver and kidney transplantation85 have been done 
successfully and should be done whenever needed. The 
patients who have undergone kidney or liver transplantation 
should be followed up regularly because of increased risks of 
renal failure, hypertension, and cardiovascular complications. 
Metabolic changes and osteoporosis may also develop. Skin 
cancers and lymphomas are more common than in the general 
population and thus, extensive exposure to the sunlight and 
smoking should be avoided. Long-term complications are 
often multifactorial but commonly related to immunosup-
pressive drugs in use.86–88
Hepatocellular carcinoma
Several population-based studies of AIP patients have shown 
an evidence of a significantly increased incidence of HCC 
in AIP compared to general population.14,15,89–91 The highest 
incidence of HCC (23%–27%, more than 60-fold increased 
risk compared to general population) was shown in the Finnish 
and Swedish patients with AIP.13,89,91 In contrast to renal insuf-
ficiency, HCC has developed in patients with both symptomatic 
and asymptomatic AIP, although the patients with manifested 
AIP are likely at higher risk. Only in one-third of the cases, 
HCC has coexisted with liver cirrhosis or well-known risk 
factors for HCC, such as viral hepatitis or heavy alcohol con-
sumption.8,13–15,85,89 Hepatoma should always be considered if 
a patient develops acute attacks or an abdominal pain after 
long-term remission or abnormally high porphyrin excretion 
pattern even at the old age.13–15 Hepatomas can be solitary or 
multiple in AIP patients,13,91 and should be treated according to 
current guidelines (ie, hepatic resection, local ablation thera-
pies, multikinase inhibitors) whenever possible.13,15,92
Since 10% of the patients with AIP die of hepatoma,91 the 
patients with AIP most likely benefit from regular screening 
for HCC after 50 years of age.13–15 Early diagnosis of HCC is 
crucial for the prognosis and can be achieved only by accurate 
radiological imaging.
Chronic pain
Among AIP patients with recurrent acute attacks, chronic 
neuropathic, myalgic, or abdominal pain usually accompanied 
by fatigue is common (18%–22%).3,17 This could be due to 
repetitive autonomic and peripheral nerve damage during 
acute attacks, and the long-term hypocaloric nutrition induc-
ing catabolic stage and muscle atrophy. The mouse model 
of AIP, which is in contrast to human autosomal-dominant 
AIP caused by compound heterozygous mutations in HMBS 
gene (HMBS -/-) and severe deficiency of HMBS enzyme, 
has developed chronic axonal motor neuropathy even in the 
absence of acute attacks and elevated ALA levels.19 In humans, 
a homozygous AIP patient has developed a chronic senso-
rimotor neuropathy associated with severe neurodegenerative 
encephalopathy and mental retardation at his early childhood 
but no chronic pain syndrome has been present.93
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The treatment options include prevention of acute attacks 
as described earlier and prolonged treatment with  gabapentin94 
or antidepressants, such as fluoxetine.49 Prophylactic heme 
infusions commonly alleviate the chronic pain syndrome.3,49 
Regular use of opiates induces tolerance to these drugs and 
high doses may increase the risk of side effects such as addic-
tion, somnolence, and apnea.
Future therapies
rh-HMBS preparation has been shown to lower plasma PBG 
levels in symptom-free patients with increased excretion of 
urinary PBG.23 The similar biochemical effect of rh-HMBS 
therapy was demonstrated in the HMBS (-/-) mouse model.95 
The rh-HMBS-enzyme replacement therapy, however, had 
no effect on the patients’ symptoms during acute attacks 
mainly due to constantly high plasma ALA levels.23 This 
may be due to the fact that the rh-HMBS included only the 
erythroid specific form of the enzyme and was not targeted 
to the liver, the main site of ALA overproduction. The 
potential development of rh-HMBS-enzyme replacement 
therapy should be focused on the delivery of an active 
enzyme into the liver restoring the normal HMBS activity 
and heme biosynthesis.
Both adenoviral-mediated and nonviral HMBS gene trans-
fers corrected the metabolic defect in the cell lines of AIP 
patients and HMBS (-/-) mice.96–98 Only virus-mediated DNA 
transfer into the liver was successful and corrected metabolic 
defect in HMBS (-/-) mice at least for a month.96,99 Adenovi-
ral cytotoxicity, especially, for hepatocytes, the immunologi-
cal response to viral antigens, and only transient transduction 
of the therapeutic gene limit potential applications of this 
method.100 Adeno-associated viral (AAV) vector encoding 
HMBS and driven by liver-specific regulatory elements, such 
as α1-microglobulin enhancer and α1-antitrypsin promoter, 
is a promising alternative to the first-generation adenoviral 
vectors, since it demonstrated long-term transgene expres-
sion of HMBS in the liver with reduced risk of side effects.101 
AAV vector encoding HMBS (recombinant AAV serotype 
5-codon-optimized human HMBS, rAAV5-cohHMBS) has 
been used in macaques.102 The safety and efficiency of AAV 
vector containing the HMBS gene is currently investigated 
in the clinical trial (Phase I).103
Small interfering RNA targeting liver ALA synthase 
results in reduction of ALA synthase mRNA and prevents 
acute attacks in AIP mouse model, and it is under develop-
ment for human studies.104 This demonstrates that downregu-
lation of liver heme biosynthesis via direct ALA synthase 
inhibitor could result in a promising future therapy.
Conclusion
Before the glucose and hematin treatment of an acute attack 
has been introduced, the mortality rate during an acute attack 
of AIP was up to 66%.105 Currently, the improved diagnostics, 
the early and effective treatment with heme preparations, and 
the prevention of acute attacks have decreased the mortality 
substantially. However, the morbidity and mortality (5%–
20%) of an acute attack is still significant if the diagnosis of 
AIP is delayed.3,8,10,11 Thus, it is important that AIP patients are 
treated in the experienced centers with facilities that enable 
monitoring of their clinical and biochemical profile.
Current options to prevent acute attack include patients 
and family doctor education and family screening for HMBS 
mutation carriers. In patients with recurrent attacks, ovarian 
suppression using hormonal interventions, prophylactic heme 
therapy, or liver transplantation should be considered to improve 
the prognosis and quality of their lives. Future therapies, such as 
enzyme or gene delivery, should demonstrate clinical efficiency 
and safety before they can be applied to the clinical use. In the 
long-term follow-up, impaired renal function and hypertension 
should be treated carefully, and screening for hepatomas should 
be considered after 50 years of age.
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